Glycemic variability and the short-term mortality of hospitalized patients with COVID-19: a meta-analysis
-
By
-
Zixuan Wang
-
Jingyi Wang
-
Qiao Wu
-
Baozeng Wang
-
June 16, 2026
-
Clinical Scorecard: Association of Glycemic Variability with Short-Term Mortality in Hospitalized COVID-19 Patients: A Meta-Analysis
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | |
| Target Population | Adult patients (≥ 18 years) hospitalized with confirmed COVID-19. |
| Care Setting | |
Key Highlights
- High glycemic variability (GV) is associated with increased risk of all-cause mortality (RR = 2.10).
- Stronger association observed in patients aged ≥ 62 years (RR = 2.79).
- Results consistent across various GV metrics and study qualities.
- Glycemic variability may inform clinical management strategies.
Guideline-Based Recommendations
Diagnosis
Management
- Consider glycemic variability as a prognostic marker in clinical management.
- Implement specific glycemic control strategies to address variability.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Hospitalized patients with COVID-19.
Glycemic control strategies may need to address variability in blood glucose levels.
Clinical Best Practices
- Incorporate glycemic variability assessment into risk stratification protocols.
- Utilize consistent metrics for measuring glycemic variability.
- Provide regular training on glycemic variability assessment for healthcare providers.
Related Resources & Content
